A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.

Authors

Shore N, Mincik I, DeGuenther M, Student V Jr, Jievaltas M, Patockova J, Simpson K, Hu CH, Huang ST, Li Y, Lee Y, Chien B, Mao J.

Journal

World J Urol

Year

2019

Volume

Apr 3

21st Century Oncology Physicians

Back
To top